Announced details
Treatment of recurrent glioblastoma
2 patients were dosed at Dose Level 4 in the Phase I trial. Long-term Stable Disease and an unconfirmed Partial Response were observed in 1 patient at Dose Level 2.
The parties are jointly developing the drug. They have nearly reached agreement with the investigator-initiated clinical trial team on the protocol for the Phase Ib trial.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
AACR 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | TUG1 ASO |
| Counterparty | Nagoya University |
| Relationship with the Company | The parties are jointly developing the drug. They have nearly reached agreement with the investigator-initiated clinical trial team on the protocol for the Phase Ib trial. |
| Applicable area | Treatment of recurrent glioblastoma |
| Usage history | 2 patients were dosed at Dose Level 4 in the Phase I trial. Long-term Stable Disease and an unconfirmed Partial Response were observed in 1 patient at Dose Level 2. |
| Source | AACR 2026 |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To report additional information on the Phase I trial presented at AACR 2026, following the interim results announced on 9 December 2025. In the Phase Ib trial, the dose and schedule will be reconsidered based on the results of the current trial.